| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2020 | 182 | 2.560 |
Why?
|
| Cyclophosphamide | 14 | 2017 | 54 | 1.560 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2017 | 19 | 1.100 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 290 | 1.020 |
Why?
|
| Mammary Neoplasms, Experimental | 4 | 2017 | 70 | 0.940 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2023 | 222 | 0.930 |
Why?
|
| Cell Line, Tumor | 29 | 2023 | 2231 | 0.810 |
Why?
|
| Breast Neoplasms | 11 | 2022 | 1502 | 0.790 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 16 | 0.750 |
Why?
|
| Neoplasm Metastasis | 6 | 2013 | 219 | 0.740 |
Why?
|
| Cell Proliferation | 11 | 2023 | 1198 | 0.720 |
Why?
|
| Angiogenesis Inhibitors | 9 | 2017 | 59 | 0.710 |
Why?
|
| Mice | 36 | 2023 | 5913 | 0.690 |
Why?
|
| Neoplasms | 7 | 2017 | 1103 | 0.680 |
Why?
|
| Neovascularization, Pathologic | 7 | 2017 | 127 | 0.580 |
Why?
|
| Cytokines | 1 | 2020 | 602 | 0.570 |
Why?
|
| Disease Models, Animal | 5 | 2013 | 1371 | 0.560 |
Why?
|
| Indoles | 5 | 2017 | 158 | 0.500 |
Why?
|
| Animals | 40 | 2023 | 15081 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2013 | 259 | 0.470 |
Why?
|
| Deoxycytidine | 2 | 2011 | 22 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2009 | 161 | 0.460 |
Why?
|
| DNA Repair | 2 | 2005 | 188 | 0.450 |
Why?
|
| Mice, SCID | 12 | 2018 | 150 | 0.450 |
Why?
|
| Melanoma | 3 | 2023 | 96 | 0.440 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 358 | 0.420 |
Why?
|
| Prodrugs | 1 | 2011 | 24 | 0.400 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 803 | 0.400 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 12 | 0.400 |
Why?
|
| Antibodies | 3 | 2009 | 141 | 0.390 |
Why?
|
| Pyrroles | 4 | 2017 | 55 | 0.390 |
Why?
|
| Humans | 49 | 2023 | 37093 | 0.390 |
Why?
|
| Neoplasm Transplantation | 7 | 2018 | 122 | 0.380 |
Why?
|
| Mice, Inbred BALB C | 8 | 2017 | 661 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 268 | 0.330 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 4 | 0.330 |
Why?
|
| Viscera | 1 | 2008 | 4 | 0.330 |
Why?
|
| Spheroids, Cellular | 3 | 2005 | 28 | 0.320 |
Why?
|
| Base Pair Mismatch | 2 | 2005 | 13 | 0.310 |
Why?
|
| Female | 28 | 2022 | 20969 | 0.310 |
Why?
|
| Camptothecin | 2 | 2017 | 20 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2020 | 1039 | 0.310 |
Why?
|
| Endothelial Cells | 7 | 2017 | 308 | 0.300 |
Why?
|
| Melanoma, Experimental | 3 | 2008 | 9 | 0.290 |
Why?
|
| Fibroblasts | 1 | 2009 | 272 | 0.290 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 37 | 0.290 |
Why?
|
| Receptor, erbB-2 | 4 | 2022 | 133 | 0.280 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 3 | 0.280 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2006 | 2 | 0.280 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2006 | 2 | 0.280 |
Why?
|
| Bromocriptine | 1 | 2006 | 7 | 0.280 |
Why?
|
| Cushing Syndrome | 1 | 2006 | 5 | 0.280 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 306 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 9 | 2011 | 502 | 0.270 |
Why?
|
| DNA Repair Enzymes | 1 | 2005 | 20 | 0.270 |
Why?
|
| Cyclin D1 | 3 | 2018 | 43 | 0.260 |
Why?
|
| Prostatic Neoplasms | 8 | 2013 | 935 | 0.260 |
Why?
|
| Adenosine Triphosphatases | 1 | 2005 | 82 | 0.260 |
Why?
|
| Tumor Burden | 5 | 2012 | 77 | 0.250 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2022 | 190 | 0.250 |
Why?
|
| Alkylating Agents | 1 | 2004 | 13 | 0.250 |
Why?
|
| Cell Movement | 3 | 2018 | 571 | 0.250 |
Why?
|
| Administration, Oral | 7 | 2016 | 224 | 0.240 |
Why?
|
| Colonic Neoplasms | 3 | 2017 | 186 | 0.230 |
Why?
|
| Mice, Nude | 10 | 2020 | 337 | 0.230 |
Why?
|
| Survival Rate | 3 | 2020 | 311 | 0.230 |
Why?
|
| Carrier Proteins | 1 | 2005 | 305 | 0.230 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 307 | 0.230 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 190 | 0.220 |
Why?
|
| Phenylurea Compounds | 2 | 2020 | 18 | 0.210 |
Why?
|
| Prognosis | 3 | 2020 | 739 | 0.210 |
Why?
|
| Apoptosis | 5 | 2017 | 1398 | 0.210 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 539 | 0.200 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 974 | 0.180 |
Why?
|
| Time Factors | 6 | 2017 | 1742 | 0.180 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 113 | 0.180 |
Why?
|
| Quinolines | 1 | 2020 | 64 | 0.180 |
Why?
|
| Blotting, Western | 4 | 2005 | 859 | 0.170 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1999 | 46 | 0.170 |
Why?
|
| Transplantation, Heterologous | 4 | 2018 | 90 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 31 | 0.170 |
Why?
|
| Thrombospondin 1 | 2 | 2012 | 23 | 0.160 |
Why?
|
| Molecular Probe Techniques | 1 | 2018 | 7 | 0.160 |
Why?
|
| Axilla | 1 | 2018 | 4 | 0.160 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 37 | 0.160 |
Why?
|
| Flavones | 1 | 2018 | 12 | 0.160 |
Why?
|
| Molecular Probes | 1 | 2018 | 23 | 0.160 |
Why?
|
| Taxoids | 2 | 2014 | 37 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 88 | 0.140 |
Why?
|
| Cell Death | 1 | 2017 | 267 | 0.140 |
Why?
|
| Male | 20 | 2023 | 20025 | 0.140 |
Why?
|
| Annexin A6 | 1 | 1996 | 17 | 0.140 |
Why?
|
| Cisplatin | 3 | 2005 | 72 | 0.140 |
Why?
|
| Blotting, Northern | 3 | 2004 | 150 | 0.140 |
Why?
|
| Base Sequence | 5 | 2004 | 997 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 45 | 0.140 |
Why?
|
| Gene Expression Profiling | 4 | 2015 | 626 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2016 | 105 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 122 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2017 | 1908 | 0.130 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 218 | 0.130 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2016 | 88 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 807 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 356 | 0.130 |
Why?
|
| Up-Regulation | 5 | 2015 | 513 | 0.130 |
Why?
|
| Curcumin | 1 | 2016 | 74 | 0.130 |
Why?
|
| Molecular Sequence Data | 5 | 2004 | 1568 | 0.130 |
Why?
|
| NF-kappa B | 1 | 2017 | 339 | 0.120 |
Why?
|
| Cell Adhesion | 1 | 2015 | 212 | 0.120 |
Why?
|
| Disease Progression | 3 | 2014 | 601 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 269 | 0.120 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 143 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 146 | 0.120 |
Why?
|
| Ultrasonic Therapy | 1 | 2013 | 4 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 112 | 0.110 |
Why?
|
| Receptor, Endothelin B | 1 | 2012 | 3 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2012 | 9 | 0.110 |
Why?
|
| Caveolin 1 | 1 | 2012 | 29 | 0.110 |
Why?
|
| Ceramides | 1 | 2012 | 42 | 0.100 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 251 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 20 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 169 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2011 | 34 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 111 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 152 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 8 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 111 | 0.090 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2010 | 23 | 0.090 |
Why?
|
| Genetic Engineering | 1 | 2010 | 33 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 623 | 0.090 |
Why?
|
| Pyridines | 1 | 2010 | 116 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2017 | 177 | 0.090 |
Why?
|
| Transfection | 2 | 2015 | 523 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2022 | 1207 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 448 | 0.080 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 22 | 0.080 |
Why?
|
| Lymphokines | 1 | 2009 | 13 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 26 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 145 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 617 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2009 | 95 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 202 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 110 | 0.070 |
Why?
|
| Cell Cycle | 3 | 2017 | 326 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2022 | 435 | 0.070 |
Why?
|
| Mutation | 2 | 2023 | 1095 | 0.070 |
Why?
|
| Azacitidine | 1 | 2005 | 22 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2005 | 10 | 0.070 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 32 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2005 | 23 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2014 | 1369 | 0.060 |
Why?
|
| CHO Cells | 1 | 2004 | 124 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 275 | 0.060 |
Why?
|
| Gene Expression | 2 | 2018 | 674 | 0.060 |
Why?
|
| Cricetinae | 1 | 2004 | 238 | 0.060 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2023 | 6 | 0.060 |
Why?
|
| HT29 Cells | 3 | 2012 | 45 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2004 | 172 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 129 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2003 | 29 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 24 | 0.060 |
Why?
|
| Cadherins | 1 | 2004 | 90 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 408 | 0.060 |
Why?
|
| Topotecan | 2 | 2013 | 4 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 515 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 17 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 474 | 0.050 |
Why?
|
| Anoikis | 1 | 2022 | 21 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 241 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2005 | 325 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 893 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2013 | 325 | 0.050 |
Why?
|
| Vinblastine | 2 | 2016 | 9 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 237 | 0.050 |
Why?
|
| Middle Aged | 3 | 2016 | 10129 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 325 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 213 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2016 | 399 | 0.050 |
Why?
|
| Aged | 3 | 2017 | 6741 | 0.050 |
Why?
|
| Protein Phosphatase 2 | 1 | 1999 | 22 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 13 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 441 | 0.040 |
Why?
|
| Tegafur | 2 | 2010 | 2 | 0.040 |
Why?
|
| Uracil | 2 | 2010 | 8 | 0.040 |
Why?
|
| Rabbits | 2 | 1996 | 283 | 0.040 |
Why?
|
| Fluorouracil | 2 | 2012 | 34 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 26 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2011 | 9 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2017 | 3 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 2017 | 27 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 80 | 0.040 |
Why?
|
| Contrast Media | 1 | 2018 | 92 | 0.040 |
Why?
|
| Caspases | 1 | 2017 | 147 | 0.040 |
Why?
|
| Nevus | 1 | 1996 | 5 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 211 | 0.040 |
Why?
|
| Stem Cells | 2 | 2010 | 141 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 65 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2016 | 45 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 78 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 207 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2015 | 18 | 0.030 |
Why?
|
| RNA Stability | 1 | 2015 | 26 | 0.030 |
Why?
|
| Cell Line | 1 | 1999 | 1354 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 54 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 103 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2B | 1 | 1994 | 1 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 1994 | 18 | 0.030 |
Why?
|
| Fecal Impaction | 1 | 2013 | 1 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2013 | 6 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1994 | 118 | 0.030 |
Why?
|
| Species Specificity | 1 | 2013 | 245 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2012 | 11 | 0.030 |
Why?
|
| Leucovorin | 1 | 2012 | 5 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 16 | 0.030 |
Why?
|
| Cell Division | 2 | 2004 | 307 | 0.030 |
Why?
|
| Injections | 1 | 2012 | 35 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2012 | 29 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 251 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 972 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 37 | 0.030 |
Why?
|
| Skin | 1 | 2013 | 174 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 1378 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 103 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 99 | 0.030 |
Why?
|
| Proteins | 1 | 1994 | 369 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 1609 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 15 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 928 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2005 | 1518 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 2379 | 0.020 |
Why?
|
| Liver | 2 | 2007 | 479 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 204 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 19 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 62 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 118 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 349 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2007 | 17 | 0.020 |
Why?
|
| Biotransformation | 1 | 2007 | 67 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2007 | 47 | 0.020 |
Why?
|
| Laminin | 1 | 2007 | 61 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2007 | 70 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2007 | 98 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 92 | 0.020 |
Why?
|
| Collagen | 1 | 2007 | 172 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 41 | 0.020 |
Why?
|
| Triazines | 1 | 2006 | 20 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 578 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 58 | 0.020 |
Why?
|
| Thromboplastin | 1 | 2005 | 5 | 0.020 |
Why?
|
| Propionates | 1 | 2005 | 26 | 0.020 |
Why?
|
| Quinazolines | 1 | 2005 | 33 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 3483 | 0.020 |
Why?
|
| Piperidines | 1 | 2005 | 77 | 0.020 |
Why?
|
| Oxygen | 1 | 2006 | 207 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2004 | 14 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2004 | 37 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2004 | 16 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 148 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 562 | 0.010 |
Why?
|
| Etoposide | 1 | 2004 | 22 | 0.010 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2003 | 3 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2003 | 17 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2004 | 77 | 0.010 |
Why?
|
| Microdissection | 1 | 2003 | 11 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 37 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2004 | 73 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 26 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 50 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 47 | 0.010 |
Why?
|
| Wound Healing | 1 | 2004 | 70 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 99 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 122 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 120 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 12 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 9 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 26 | 0.010 |
Why?
|
| Drinking | 1 | 2002 | 38 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 434 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1015 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 1994 | 29 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1994 | 49 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1994 | 191 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 1994 | 140 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 1994 | 249 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 1180 | 0.010 |
Why?
|